FDA Poised to Loosen Peptide Access—But Staff Doubts, While US Probes Merck/AbbVie China Trials

US regulators are weighing whether to ease access to certain peptide products even as internal reviews and FDA staff raise doubts about their evidence base. Multiple reports on June 30, 2026 describe documents reviewing peptide research that highlight a lack of strong proof for both efficacy and safety. At the same time, an FDA advisory panel scheduled for later this month is expected to consider changes that could expand availability. Reuters also reports that FDA staff are questioning peptides backed by Robert F. Kennedy Jr. ahead of the advisory panel review, while another outlet notes the panel includes experts promoting unproven treatments. The geopolitical angle is less about battlefield dynamics and more about regulatory sovereignty, information integrity, and cross-border pharmaceutical governance. A potential shift in US access rules for peptides could accelerate demand for less-validated therapies, intensifying pressure on US oversight capacity and shaping how global suppliers market similar products. Meanwhile, the US House committee’s decision to open an investigation into Merck and AbbVie China drug trials adds a parallel risk channel: scrutiny of trial conduct and data integrity tied to China-linked operations. The combined picture suggests a US push to reassert control over biomedical evidence standards, with companies and China-based trial ecosystems facing reputational and compliance costs. Market implications are likely to concentrate in biotech and specialty pharma rather than broad macro assets. If FDA moves toward easing access, investors may reprice segments tied to peptide manufacturing, distribution, and adjacent supplements, while also increasing regulatory overhang for firms reliant on weaker clinical packages. The investigation into Merck and AbbVie China trials can raise perceived compliance risk and delay timelines for China-related submissions, potentially affecting revenue visibility for large-cap pharma and their China exposure. In trading terms, the most sensitive instruments would be US-listed pharma/biotech equities and risk premia for clinical-stage developers; however, the direction is likely mixed—short-term relief for “access” narratives, offset by longer-term uncertainty around trial credibility. What to watch next is the FDA advisory panel’s vote and the agency’s subsequent decision on whether to broaden access for peptides. Key trigger points include the panel’s assessment of safety signals, the strength of clinical evidence presented, and whether FDA staff concerns about Kennedy-backed products are addressed in the final record. On the oversight front, the House committee investigation’s scope—documents requested, witness list, and any allegations about trial methodology—will determine whether this becomes a broader sanctions/compliance story or remains contained to corporate governance. Over the next weeks, monitor FDA communications, panel transcripts, and any follow-on regulatory actions that could tighten labeling, restrict indications, or impose additional post-market requirements.

Geopolitical Implications

• 01

  US regulatory choices on peptides will shape global biomedical standards and supplier behavior.

• 02

  Congressional scrutiny of China-linked trials signals tighter US tolerance for trial-data integrity risks.

• 03

  Potential FDA easing despite evidence gaps could trigger political backlash and further politicize health oversight.

Key Signals

• —Panel vote and FDA’s final access decision for peptides.
• —How FDA addresses staff concerns about Kennedy-backed products in the official record.
• —House committee investigation scope and any trial-methodology allegations.
• —Merck and AbbVie disclosures on China trial timelines and compliance controls.